






A preclinical Johns Hopkins study, co-authored by Kurve CEO Marc Giroux, found that intranasal delivery reached the brain far more selectively than injection, in rodents and a non-human primate.
Read peer reviewViaNase™ is available through Kurve’s clinical studies and FDA expanded access (compassionate use). Tell us who you are and we’ll guide you to the right route.
